Edition:
Deutschland

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

61.84USD
23 May 2018
Change (% chg)

$0.45 (+0.73%)
Prev Close
$61.39
Open
$61.26
Day's High
$61.97
Day's Low
$61.26
Volume
1,241,725
Avg. Vol
1,831,124
52-wk High
$64.60
52-wk Low
$43.40

ABT.N

Chart for ABT.N

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Buy/Sell

Sell Hold Buy
1.79 Mean rating from 19 analysts

Overall

Beta: 1.57
Market Cap(Mil.): $95,559.38
Shares Outstanding(Mil.): 1,737.44
Dividend: 0.26
Yield (%): 1.93

BRIEF-Abbott Expands Cardiac Arrhythmias Portfolio With FDA Clearance Of Advanced Mapping Catheter

* ABBOTT EXPANDS CARDIAC ARRHYTHMIAS PORTFOLIO WITH FDA CLEARANCE OF ADVANCED MAPPING CATHETER

BRIEF-Abbott's Xience Sierra Heart Stent Receives National Reimbursement In Japan

* ABBOTT'S XIENCE SIERRA™ HEART STENT RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PEOPLE WITH CORONARY ARTERY DISEASE Source text for Eikon: Further company coverage:

Photo

Exclusive - India rejects U.S. request on price caps on medical devices: sources

NEW DELHI India has told the United States it won't abstain from capping prices for more medical devices, regardless of pressure to rethink its stance after price controls on heart stents and knee implants spoilt the market for some U.S. firms, sources familiar with the matter said.

BRIEF-Abbott Laboratories Says Shareholders Rejected Proposal Requesting Board Of Directors Adopt Policy That Board Chairman Be Independent Director

* ABBOTT LABORATORIES SAYS SHAREHOLDERS REJECTED PROPOSAL REQUESTING CO'S BOARD OF DIRECTORS ADOPT POLICY THAT BOARD CHAIRMAN BE INDEPENDENT DIRECTOR Source text: (https://bit.ly/2KqCwQY) Further company coverage:

BRIEF-Abbott Laboratories - Co, Sanquin Sign Multiple-Year Contract For Supply Of Primary Serological Equipment And Consumables

* ABBOTT LABORATORIES - CO, SANQUIN SIGN MULTIPLE-YEAR CONTRACT FOR SUPPLY OF PRIMARY SEROLOGICAL EQUIPMENT AND CONSUMABLES Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Factbox - U.S. companies with exposure to Russia

Although the United States and Russia have imposed economic sanctions on each other since 2014, several large U.S. corporations, including PepsiCo Inc and McDonald's Corp , still count Russia as a growth market.

FACTBOX-U.S. companies with exposure to Russia

April 18 Although the United States and Russia have imposed economic sanctions on each other since 2014, several large U.S. corporations, including PepsiCo Inc and McDonald's Corp, still count Russia as a growth market.

Photo

Abbott sticks to earlier forecasts, disappoints investors

Abbott Laboratories' just beat expectations for first quarter profits and revenue on Wednesday but stuck to a full-year profit forecast some investors had expected would be raised, sending the healthcare company's shares lower.

UPDATE 3-Abbott sticks to earlier forecasts, disappoints investors

* Analysts cite disappointment on whisper numbers among investors

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -1.01%
Rohstoffe -0.41%
Industrie -0.14%
Konjunktur abhängige Waren & Dienstleistungen +0.32%
Konjunktur unabhängige Waren & Dienstleistungen -0.57%
Finanzindustrie +0.11%
Pharma +0.74%
Technologie -0.31%
Telekommunikation +0.41%